Literature DB >> 17221282

Continuous ambulatory peritoneal dialysis in patients with renal failure due to multiple myeloma.

Mufazzal Ahmad1.   

Abstract

Continuous ambulatory peritoneal dialysis (CAPD) is being used only in limited number of patients with renal failure due to multiple myeloma, despite having better preservation of hemoglobin, higher clearance of paraproteins, and higher chances of recovery of renal function than maintenance hemodialysis. We are reporting our short-term experience of five patients with multiple myeloma who presented with renal failure and required long term continuous ambulatory peritoneal dialysis for the treatment of uremia.

Entities:  

Mesh:

Year:  2007        PMID: 17221282     DOI: 10.1007/s11255-006-9160-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  12 in total

1.  Multiple myeloma: review of 869 cases.

Authors:  R A Kyle
Journal:  Mayo Clin Proc       Date:  1975-01       Impact factor: 7.616

2.  Multiple myeloma with renal failure. A case for intensive treatment.

Authors:  D C Harris; L S Ibels; R B Ravich; J P Isbister; J V Wells
Journal:  Aust N Z J Med       Date:  1983-04

3.  Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-12

4.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; A P Maxwell; I Bruce; B G Murphy; C C Doherty
Journal:  Ir J Med Sci       Date:  1993-06       Impact factor: 1.568

5.  Acute renal failure in patients with multiple myeloma.

Authors:  D J Cohen; W H Sherman; E F Osserman; G B Appel
Journal:  Am J Med       Date:  1984-02       Impact factor: 4.965

6.  Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment.

Authors:  N Iggo; A B Palmer; A Severn; J A Trafford; G J Mufti; D Taube; V Parsons
Journal:  Q J Med       Date:  1989-10

7.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

8.  Renal function recovery in end-stage renal disease.

Authors:  V Pichette; S Quérin; M Desmeules; J Ethier; P Copleston
Journal:  Am J Kidney Dis       Date:  1993-09       Impact factor: 8.860

9.  Use of peritoneal dialysis in the treatment of patients with renal failure and paraproteinemia.

Authors:  S J Rosansky; F W Richards
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

10.  Severe renal failure in multiple myeloma.

Authors:  F G Cosio; T V Pence; F L Shapiro; C M Kjellstrand
Journal:  Clin Nephrol       Date:  1981-04       Impact factor: 0.975

View more
  1 in total

Review 1.  Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.

Authors:  Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2007-12-08       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.